Details for Patent: 9,512,084

Which drugs does patent 9,512,084 protect, and when does it expire?

Patent 9,512,084 protects RHAPSIDO and is included in one NDA.

This patent has eighty-two patent family members in forty-one countries.

Summary for Patent: 9,512,084

Title:	Amino pyrimidine derivatives
Abstract:	The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
Inventor(s):	Daniela Angst, François Gessier, Anna Vulpetti
Assignee:	Novartis AG
Application Number:	US14/540,140
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 9,512,084

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	RHAPSIDO	remibrutinib	TABLET;ORAL	218436-001	Sep 30, 2025		RX	Yes	Yes	9,512,084		Y	Y

International Family Members for US Patent 9,512,084

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3299368		C20265019	Finland
European Patent Office	3299368		CA 2026 00037	Denmark
European Patent Office	3299368		PA2026528	Lithuania
European Patent Office	3299368		LUC50061	Luxembourg
European Patent Office	3299368		301397	Netherlands
Argentina	098549